Understand the source comparison
Back Pain Peptides 2026 Update: Clinical Evidence Comparison
BPC-157 VEGF upregulation, angiogenesis promotion, collagen synthesis acceleration Preclinical + case series (no RCTs in humans for spinal applications) 250–500mcg subcutaneously daily for 8–12 weeks Acute disc herniation, annular tears, ligament microtears St
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, angiogenesis promotion, collagen synthesis acceleration
- Preclinical + case series (no RCTs in humans for spinal applications)
- 250–500mcg subcutaneously daily for 8–12 weeks
- Acute disc herniation, annular tears, ligament microtears
- Strongest preclinical evidence; human data is observational but consistent across case reports. Best suited for acute tissue damage with vascular insufficiency.
- TB-500 (Thymosin Beta-4)
- Actin regulation, inflammatory cytokine modulation, cell migration to injury sites
- One prospective cohort study (n=47) published 2024; multiple case series
- 2mg subcutaneously twice weekly for 6–8 weeks
- Chronic facet joint inflammation, tendinopathy, ligament laxity
- Human evidence superior to BPC-157 for chronic inflammatory conditions. Dosing frequency is a compliance barrier for some patients.
- GHK-Cu (Copper Peptide)
- Collagen I/III synthesis, antioxidant activity, MMP regulation
- Preclinical + dermatological studies; no spinal-specific RCTs
- 2–5mg subcutaneously weekly OR 10mg/mL topical cream applied daily
- Age-related disc degeneration, oxidative stress-related pathology
- Evidence weakest among the three for direct structural repair. May provide adjunct benefit in oxidative stress-dominant pathologies but lacks standalone efficacy data.